Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 13/20 | 0.56 |
| ▸ | APOB | P04114 | 9/20 | 0.56 |
| ▸ | SMO | Q99835 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8211359 | 0.97 | MTTP (0.56) | MTTPAPOBSMOKDM4EGAA | |
| SCHEMBL8227456 | 0.97 | MTTP (0.55) | MTTPAPOBSMOKDM4EGAA | |
| SCHEMBL8230812 | 0.97 | MTTP (0.55) | MTTPAPOBSMOKDM4EGAA | |
| SCHEMBL8208351 | 0.97 | MTTP (0.55) | MTTPAPOBSMOKDM4EGAA | |
| SCHEMBL8213416 | 0.95 | MTTP (0.58) | MTTPAPOBSMOKDM4EGAA | |
| SCHEMBL8208562 | 0.93 | MTTP (0.56) | MTTPAPOBSMOKDM4EGAA | |
| SCHEMBL8201182 | 0.92 | MTTP (0.57) | MTTPAPOBSMOKDM4EGAA | |
| SCHEMBL8213404 | 0.91 | MTTP (0.58) | MTTPAPOBSMOKDM4EGAA | |
| SCHEMBL8213608 | 0.91 | MTTP (0.60) | MTTPAPOBSMOKDM4EGAA | |
| SCHEMBL691193 | 0.91 | MTTP (0.54) | MTTPAPOBSMOKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806149-A1 | SOLID MEDICINAL PREPARATION IMPROVED IN SOLUBILITY AND STABILITY AND PROCESS FOR PRODUCING THE SAME | Japan Tobacco, Inc. (JP) | 2007-07-11 | — | — | EP | claimed |
| US-20060153913-A1 | Solid formulation with improved solubility and stability, and method for producing said formulation | JAPAN TOBACCO INC. (JP) | 2006-07-13 | — | — | US | claimed |
| EP-1099438-A2 | Use of APO B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1099439-A2 | Use of apo B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1099441-A2 | Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-7482368-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1404653-B1 | TRIAMIDE-SUBSTITUTED INDOLES, BENZOFURANES AND BENZOTHIOPHENES AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND/OR APOLIPOPROTEIN B (APO B) SECRETION | PFIZER PROD INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7348355-B2 | Treating obesity with the Microsomal triglyceride transfer protein inhibitor (S) N-{2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-1-methyl-5-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamido]-1H-indole-2-carboxamide and another lipid lowering agent such as a statin or fibrate | PFIZER INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1806149-A1 | SOLID MEDICINAL PREPARATION IMPROVED IN SOLUBILITY AND STABILITY AND PROCESS FOR PRODUCING THE SAME | Japan Tobacco, Inc. (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20070027093-A1 | Anorectic | JAPAN TOBACCO INC. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027093-A1 | Anorectic | JAPAN TOBACCO INC. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20060194772-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2006-08-31 | — | — | US | disclosed |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| JP-2001172180-A | USE OF APO-B SECRETION/MTP INHIBITOR | PFIZER PROD INC | 2001-06-26 | — | — | JP | disclosed |
| EP-1099438-A2 | Use of APO B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1099439-A2 | Use of apo B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1099441-A2 | Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| US-6121283-A | Apo B-secretion/MTP inhibitory amides | PFIZER INC (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0944602-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023593-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194772-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | MTTP 3/4885APOB 1/4885SMO 4486/4885 |
| US-20070027093-A1 | Anorectic | DGAT1, DGAT2, GPR119 | MTTP 1422/4885APOB 4701/4885SMO 1831/4885 |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | MTTP 3/4885APOB 1/4885SMO 4760/4885 |
| US-20060153913-A1 | Solid formulation with improved solubility and stability, and method for producing said formulation | ABCG2, SORD, SRI | MTTP 1276/4885APOB 2105/4885SMO 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.